


How can you improve HPV vaccination uptake?


GARDASIL® 9
Human Papillomavirus
9-valent Vaccine, Recombinant



How can you help protect people against certain HPV-related cancers?





Both school immunisation teams and primary care teams have an important role in offering HPV vaccination to potentially eligible people^{1,2}



The HPV programme is primarily delivered by School Age Immunisation Services (SAIS), however provision can vary from area to area^{3,4}



Some young people miss their immunisation in school and may not be proactively offered HPV vaccination after leaving full-time education



That's where primary care comes in



Provide young people with a second chance to receive their HPV vaccination



School nurses have a role in making young people aware that they should contact their GP if they have missed their vaccination in school



GP practices can offer HPV vaccination opportunistically or on request to potentially eligible people aged between 14 and 25 years who missed their scheduled vaccination in school²



Vaccines given to eligible young people in General Practice will attract an item of service fee of £10.06 per dose administered^{2,5}

Can you identify people in your practice who have missed their vaccination?



Want to learn more?

Click on the link below to access more resources on HPV including:

[What is HPV and its associated risks?](#)

[What is the impact of HPV vaccination to date?](#)

[What strategies can GP practices implement to increase HPV vaccination rates?](#)

Clicking the link above will take you to a promotional MSD webpage

Gardasil® 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:^{6,7}

- Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types
- Genital warts (*Condyloma acuminata*) caused by specific HPV types

Please refer to the Summary of Product Characteristics for further information prior to making any prescribing decisions.^{6,7}

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (Tel: 0208 154 8000). By clicking the above link, you will leave the MSD website and be taken to the MHRA website.

References: 1. UK Health Security Agency. Human Papillomavirus (HPV): the green book, chapter 18a. March 2022. Available at: <https://www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a>. Last accessed: July 2023. 2. NHS England and NHS Improvement. GP letter on vaccination and immunisation changes for 2021/22. March 2021. Available at: https://www.england.nhs.uk/wp-content/uploads/2021/03/B0434_Update-on-vaccination-and-immunisation-changes-for-202122-v4.pdf. Last accessed: July 2023. 3. UK Health Security Agency. Human papillomavirus (HPV) vaccine coverage estimates in England: 2020 to 2021. December 2021. Available at: <https://www.gov.uk/government/statistics/human-papillomavirus-hpv-vaccine-coverage-estimates>. Last accessed: July 2023. 4. UK Health Security Agency. Supporting Immunisation Programmes. February 2023. Available at: <https://www.gov.uk/government/publications/health-protection-in-schools-and-other-childcare-facilities/supporting-immunisation-programmes>. Last accessed: July 2023. 5. NHS England. Changes to the GP Contract in 2023/24. Available at: <https://www.england.nhs.uk/long-read/changes-to-the-gp-contract-in-2023-24/#immunisations-and-vaccinations>. Last accessed: July 2023. 6. Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)). Summary of Product Characteristics (SPC) for GB. Available at: <https://www.emcpi.com/pi/32240>. Last accessed: July 2023. 7. Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)). Summary of Product Characteristics (SPC) for NI. Available at: <https://www.emcpi.com/pi/ni/496>. Last accessed: July 2023.

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.
Registered in England No. 233687
© Merck Sharp & Dohme (UK) Limited 2023. All rights reserved.
GB-GSL-00384 | August 2023